falsefalse

Optimizing CAR T-Cell Therapy in DLBCL With Community and Academic Perspectives - Episode 7

Safety Considerations for CAR T-Cell Therapy in R/R DLBCL

,

Experts discuss strategies for monitoring and managing cytokine release syndrome (CRS) and neurotoxicity, the influence of key takeaways from cohorts 4 and 6 of the ZUMA-1 trial on their practice, and how post- chimeric antigen receptor T-cell therapy (CAR T) follow-up care is managed between academic and community settings.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    • What are your strategies for monitoring and managing CRS and neurotoxicity?
    • How did the key takeaways from cohorts 4 and 6 of the ZUMA-1 trial influence your practice?
    • How do you manage post–CAR T follow-up care between academic and community settings?
    x